Avenue Therapeutics, Inc. financial data

Symbol
ATXI on OTC
Location
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 33.8 % -78.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.18M shares +122%
Common Stock, Shares, Outstanding 3.18M shares +168%
Entity Public Float 3.91M USD -54.1%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 3.18M shares +185%
Weighted Average Number of Shares Outstanding, Diluted 8.2M shares +459%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.4M USD
Research and Development Expense 3.5M USD -38.1%
General and Administrative Expense 4.27M USD -15.9%
Operating Income (Loss) -6.36M USD +40.7%
Nonoperating Income (Expense) 32K USD -73.8%
Net Income (Loss) Attributable to Parent 335K USD
Earnings Per Share, Basic -1 USD/shares -108%
Earnings Per Share, Diluted 0.06 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.33M USD -32.4%
Assets 4.16M USD -16.6%
Accounts Payable, Current 155K USD +98.7%
Liabilities, Current 1.33M USD +14.5%
Liabilities 1.33M USD +14.5%
Retained Earnings (Accumulated Deficit) -104M USD -6.27%
Stockholders' Equity Attributable to Parent 4.06M USD -14.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2.83M USD -26%
Liabilities and Equity 4.16M USD -16.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.19M USD +62%
Net Cash Provided by (Used in) Financing Activities 2.09M USD -53.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 3.18M shares +168%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 35M USD -1.94%
Deferred Tax Assets, Gross 35M USD -1.94%
Deferred Tax Assets, Operating Loss Carryforwards 27.1M USD -0.75%
Preferred Stock, Shares Issued 250K shares 0%
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 108M USD +5.29%
Preferred Stock, Shares Outstanding 250K shares 0%
Share-based Payment Arrangement, Expense 1.21M USD -3.04%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%